|Bid||0.0000 x 3000|
|Ask||0.0000 x 29200|
|Day's Range||1.3100 - 1.3950|
|52 Week Range||0.9900 - 5.1900|
|Beta (5Y Monthly)||1.45|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.00|
Novo Nordisk's (NVO) semaglutide 2.0 mg demonstrates superior reduction in HbA1c versus once-weekly semaglutide 1.0 mg in people with type II diabetes.
Kodiak Sciences (KOD) completes recruitment in the pivotal phase IIb/III DAZZLE study, currently evaluating KSI-301 for the treatment of patients with wet age-related macular degeneration.
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...